Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer | Completed | Breast Cancer | Drug, Other - sulindac, laboratory biomarker analysis | National Cancer Institute (NCI), University of Arizona, NIH, Other | Female | 18 Years - 65 Years | Phase 1 | Interventional | RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent breast cancer. PURPOSE: This randomized phase I trial is studying the effects of sulindac, to prevent breast cancer, in women at high risk for breast cancer. | |
|
Clinicaltrials.gov | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | Completed | Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia | Biological, Biological, Other, Other, Other, Other, Other, Genetic - DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, enzyme-linked immunosorbent assay, reverse transcriptase-polymerase chain reaction | City of Hope Medical Center, National Cancer Institute (NCI), Other, NIH | 18 Years - 65 Years | Phase 1 | Interventional | RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving fusion protein cytokine therapy together with rituximab may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of fusion protein cytokine therapy when given after rituximab in treating patients with B-cell non-Hodgkin lymphoma. | ||
|
Clinicaltrials.gov | Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia | Unknown status | Leukemia | Drug, Drug, Drug, Other, Other - cytarabine, daunorubicin hydrochloride, everolimus, laboratory biomarker analysis, pharmacological study | Institut de Recherche Clinique sur les Cancers et le Sang, Other | 18 Years - 65 Years | Phase 1 | Interventional | RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Everolimus may help cytarabine and daunorubicin work better by making cancer cells more sensitive to chemotherapy. Giving everolimus together with cytarabine and daunorubicin may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with cytarabine and daunorubicin in treating patients with relapsed acute myeloid leukemia. | ||
|
Clinicaltrials.gov | Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma | Withdrawn | Lymphoma | Biological, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Genetic, Other, Other - denileukin diftitox, cyclophosphamide, cytarabine, doxorubicin hydrochloride, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, protein expression analysis, flow cytometry, laboratory biomarker analysis | University of Miami, Other | 18 Years - 65 Years | N/A | Interventional | RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combinations of biological substances in denileukin diftitox may be able to carry cancer-killing substances directly to non-Hodgkin lymphoma cells. Giving combination chemotherapy together with denileukin diftitox may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving combination chemotherapy together with denileukin diftitox works in treating patients with newly diagnosed T-cell non-Hodgkin lymphoma. | ||
|
Clinicaltrials.gov | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | Withdrawn | Multiple Myeloma, Plasma Cell Myeloma | Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Drug, Genetic, Genetic, Other, Procedure - bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation | Southwest Oncology Group, National Cancer Institute (NCI), Other, NIH | 18 Years - 65 Years | Phase 2 | Interventional | RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide and lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, cisplatin, doxorubicin hydrochloride, cyclophosphamide, etoposide, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combining chemotherapy with autologous stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving bortezomib, thalidomide, and combination chemotherapy before and after transplant and lenalidomide after transplant may be an effective treatment for multiple myeloma. PURPOSE: This phase II trial is studying how well giving bortezomib, thalidomide, and lenalidomide together with combination chemotherapy and autologous stem cell transplant works in treating patients with newly diagnosed multiple myeloma. | ||
|
Clinicaltrials.gov | Bowman-Birk Inhibitor Concentrate in Healthy Men | Completed | Healthy, no Evidence of Disease | Drug, Other, Other, Other - Bowman-Birk inhibitor concentrate, placebo, pharmacological study, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | Male | 18 Years - 65 Years | Phase 1 | Interventional | This randomized phase I trial is studying the side effects and best dose of Bowman-Birk inhibitor concentrate in healthy men. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Bowman-Birk inhibitor concentrate may prevent cancer. | |
|
Clinicaltrials.gov | Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants | Terminated | Healthy, no Evidence of Disease, Obesity | Behavioral, Behavioral, Other - behavioral dietary intervention, telephone-based intervention, laboratory biomarker analysis | Northwestern University, Avon Foundation Center of Excellence, National Cancer Institute (NCI), Other, Other, NIH | Female | 18 Years - 65 Years | N/A | Interventional | The purpose of this study is to study the relationships between obesity, hormones and menopausal status, and breast cancer. The researchers would like to study whether a type of nutritional intervention, called a time-restricted diet or tRD, is easy to maintain using a smartphone application; the researchers also want to study the effect that a tRD has on weight control, hormones, and breast tissue. A tRD is a type of diet that requires people to restrict their daily eating to a specific time frame each day. The researchers think that this might be an effective and manageable way to control weight. | |
|
Clinicaltrials.gov | Photodynamic Therapy Using Lutetium Texaphyrin in Treating Patients With Cervical Intraepithelial Neoplasia | Terminated | Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 2, Cervical Intraepithelial Neoplasia Grade 3 | Drug, Drug, Procedure, Other - motexafin lutetium, photodynamic therapy, loop electrosurgical excision procedure, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | Female | 18 Years - 65 Years | Phase 1 | Interventional | Phase I trial to study the effectiveness of photodynamic therapy with lutetium texaphyrin in treating patients who have cervical intraepithelial neoplasia. Photodynamic therapy uses light and drugs such as lutetium texaphyrin that make abnormal cells more sensitive to light and may kill abnormal cells in the cervix and prevent the development of cervical cancer | |
Clinicaltrials.gov | Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma | Completed | Precancerous Condition | Drug, Other, Other - sulindac, placebo, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - 65 Years | Phase 2 | Interventional | This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles. | ||
|
Clinicaltrials.gov | Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers | Completed | Colorectal Cancer, Healthy, no Evidence of Disease | Drug, Other, Other, Other - linaclotide acetate, placebo, pharmacological study, laboratory biomarker analysis | Mayo Clinic, National Cancer Institute (NCI), Other, NIH | 18 Years - 65 Years | Phase 1 | Interventional | This randomized phase I trial studies the side effects and best dose of linaclotide acetate in preventing colorectal cancer in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of linaclotide acetate may prevent colorectal cancer. | ||
|
Clinicaltrials.gov | Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers | Terminated | Anxiety Disorder, Colon Cancer, Depression, Fatigue, Rectal Cancer | Other, Procedure, Other, Other, Other - educational intervention, CAM exercise therapy, caregiver-related intervention or procedure, questionnaire administration, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | 18 Years - 65 Years | N/A | Interventional | This randomized pilot trial studies mindfulness-based program in educating patients with colorectal cancer and their caregivers. A mindfulness-based exercise video may help reduce stress and fatigue in patients with colorectal cancer and their caregivers. | ||
|
Clinicaltrials.gov | Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | Active, not recruiting | AIDS-related Non-Hodgkin Lymphoma, AIDS-related Plasmablastic Lymphoma, AIDS-related Primary Effusion Lymphoma, HIV Infection | Drug, Biological, Other, Other - busulfan, lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells, pharmacological study, laboratory biomarker analysis | City of Hope Medical Center, Other | 18 Years - 65 Years | Phase 1 | Interventional | This pilot clinical trial studies gene therapy after frontline chemotherapy in treating patients with acquired immune deficiency syndrome (AIDS)-related non-Hodgkin lymphoma (NHL). Placing genes for anti-human immunodeficiency virus (HIV) ribonucleic acid (RNA) into stem/progenitor cells may make the body build an immune response to AIDS. Giving the chemotherapy drug busulfan before gene therapy can help gene-modified cells engraft and work better. | ||
|
Clinicaltrials.gov | Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment | Unknown status | Leukemia | Genetic, Genetic, Genetic, Genetic, Genetic, Genetic, Other - DNA methylation analysis, RNA analysis, gene expression analysis, microarray analysis, mutation analysis, nucleic acid sequencing, laboratory biomarker analysis | National Cancer Institute (NCI), NIH | 18 Years - 65 Years | Observational | RATIONALE: Studying samples of bone marrow and blood from patients with cancer who failed treatment may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer resistance. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies biomarkers in samples from adult patients with acute myeloid leukemia who failed standard-of-care treatment. | |||
|
Clinicaltrials.gov | Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers | Terminated | Healthy, no Evidence of Disease | Drug, Other, Other, Other, Other - retinoid 9cUAB30, placebo, pharmacological study, laboratory biomarker analysis, cancer prevention | National Cancer Institute (NCI), NIH | 18 Years - 65 Years | Phase 1 | Interventional | This randomized phase I trial studies the side effects and the best dose of retinoid 9cUAB30 in healthy volunteers. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of retinoid 9cUAB30 may keep cancer from forming. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
